TG Therapeutics (NASDAQ:TGTX) Hits New 52-Week High - Should You Buy?

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $43.89 and last traded at $43.46, with a volume of 1553793 shares traded. The stock had previously closed at $42.03.

Wall Street Analysts Forecast Growth

TGTX has been the topic of a number of recent research reports. HC Wainwright reissued a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $40.80.

TG Therapeutics Price Performance

The firm has a market capitalization of $6.90 billion, a P/E ratio of -434.36 and a beta of 2.21. The company has a fifty day moving average of $38.56 and a 200 day moving average of $33.24. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. The business had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. Sell-side analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Institutional Trading of TG Therapeutics

Several large investors have recently modified their holdings of TGTX. Vermillion Wealth Management Inc. bought a new stake in TG Therapeutics in the 4th quarter valued at about $30,000. NBC Securities Inc. raised its stake in shares of TG Therapeutics by 82,300.0% in the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 823 shares during the last quarter. Golden State Wealth Management LLC boosted its position in shares of TG Therapeutics by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 433 shares during the last quarter. Quadrant Capital Group LLC grew its holdings in TG Therapeutics by 137.1% during the fourth quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock worth $51,000 after buying an additional 975 shares in the last quarter. Finally, Blue Trust Inc. raised its position in TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 371 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.